权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Studies on DEVELOPMENT OF ImMUNOTHERAPY FOR ORAL CANCERS BY INTERLEUKIN 2

白细胞介素2免疫治疗口腔癌的研究进展

基本信息

批准号：
60870071
负责人：
FUJIBAYASHI Takashi
金额：
$ 4.48万
依托单位：
TOKYO MEDICAL AND DENTAL UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Developmental Scientific Research
财政年份：
1985
资助国家：
日本
起止时间：
1985 至 1987
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-60870071/
关键词：
INTERLEUKIN 2 ORAL CANCER Natural Killer Cell (NK)Lymphokine-Activated Killer Cell (LAK)Peripheral Blood Lymphocytes (PBL)Lymph Nodal Cell (LNC)Tumor Infiltrating Lymphocytes (TIL)初期第2相臨床試験 NK細胞 LAK細胞癌の免疫療法インターロイキン【II】

项目摘要

The lymphocytes from oral cancer patients have been to be able to generate anti-tumor killer activities by incubating with interleukin 2 (IL2) in vitro. Peripheral blood lymphocytes (PBL), lymphonodal cells (LNC) and tumoe infiltrating lymphocytes (TIL) have been examined for the sourse of the activated killer cells, and cell surface markers of those cells have been analysed by monoclonal antibodies. Then, the early phase II clinical study of immounotherapy with IL-2 on oral cancer patients has been performed.The augumentation of natural killer (NK) activity and the generation of lymphokine activated killer (LAK) activity were observed by in vitro incubation of PBL with IL-2 for 5 days. No significant difference was found in the augumentation of NK and LAK activities. by IL-2 between healthy donors and oral cancer patients and / or tumor stages. LNC from oral cancer patients also showed high NK activity after the activation by IL-2, however, LAK activity of LNC were significantly lower than that of PBL.Cell surface markers of precourser lymphocytes which generate NK and LAK activites expressed either CD3 CD16 or CD3 Leu7, however, possibility of T lymphocytes expreesing CD3 could not be rouled out in case of LNC.As for the early phase II clinical trial, seven oral cancer patients have been treated by intralesional injection of IL-2, and nine similar patients have been treated by intra venous rout. Obvious tumor reduction effect has been observed in some cases of intralesional immunotherapy. NK and LAK activeties of IL-2 treated patients have been also examined.

口腔癌患者的淋巴细胞已经能够通过与白介素2(IL2)体外孵育而产生抗肿瘤杀伤活性。对外周血淋巴细胞(PBL)、淋巴结节细胞(LNC)和肿瘤浸润性淋巴细胞(TIL)进行了活化杀伤细胞来源的检测，并用单抗分析了这些细胞的细胞表面标志。在此基础上，进行了IL-2免疫治疗口腔癌患者的早期II期临床研究，观察IL-2与PBL体外孵育5天后自然杀伤(NK)活性和淋巴因子激活的杀伤(LAK)活性的增强情况。NK、LAK活性升高无明显差异。IL-2在健康献血者与口腔癌患者和/或肿瘤分期之间的关系。口腔癌患者的LNC经IL-2激活后也表现出较高的NK活性，但LNC的LAK活性明显低于PBL。产生NK和LAK活性的前驱淋巴细胞的细胞表面标志表达CD3 CD16或CD3 Leu7，但LNC不能清除表达CD3的T淋巴细胞。瘤内免疫治疗在某些病例中观察到了明显的减瘤效果。同时检测IL-2治疗后患者的NK、LAK活性。